| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Perspectives |
1 From the Department of Medicine, County Hospital, Kalmar, Sweden, and the Department of Cardiovascular Medicine, University of New South Wales, The Prince of Wales Hospital, Sydney, Australia.
ABSTRACT
Both markedly and mildly elevated circulating homocysteine concentrations are associated with increased risk of vascular occlusion. Here we review possible mechanisms that mediate these effects. Inborn errors of homocysteine metabolism result in markedly elevated plasma homocysteine (200–300 µmol/L) and thromboembolic (mainly venous) disease: treatment to lower but not to normalize these concentrations prevents vascular events. Mild homocysteine elevation (>15 µmol/L) occurs in 
20–30% of patients with atherosclerotic disease. Usually, this is easily normalized with oral folate and ongoing trials are assessing the effect of folate treatment on outcomes. Although there is evidence of endothelial dysfunction with both markedly and mildly elevated homocysteine concentrations, the elevated homocysteine concentration in atherosclerotic patients is also associated with most standard vascular risk factors, and importantly, with early decline in renal function, which is common in atherosclerosis. Decline in renal function alone causes elevated plasma homocysteine (and cysteine). These observations suggest that mild hyperhomocysteinemia could often be an effect rather than a cause of atherosclerotic disease. Data on the common C677T methylenetetrahydrofolate reductase polymorphism supports this, in that, although homozygosity is a frequent cause of mild hyperhomocysteinemia when plasma folate is below median population concentrations, it appears not to increase cardiovascular risk. Indeed, there is recent evidence suggesting an acute antioxidant effect of folic acid independent of its effect on homocysteine concentrations. This antioxidant mechanism may oppose an oxidant effect of homocysteine and be relevant to treatment of patients with vascular disease, especially those with chronic renal insufficiency. Such patients have moderately elevated plasma homocysteine and greatly increased cardiovascular risk that is largely unexplained.
Key Words: Homocysteine • cardiovascular disease • methylenetetrahydrofolate reductase • folic acid • oxidative stress • thromboembolism • renal function
This article has been cited by other articles:
|
|
 |
|
  C. Antoniades, A. S. Antonopoulos, D. Tousoulis, K. Marinou, and C. Stefanadis Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials Eur. Heart J., January 1, 2009; 30(1): 6 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Liu, Q. Wang, H. Guo, M. Xia, Q. Yuan, Y. Hu, H. Zhu, M. Hou, J. Ma, Z. Tang, et al. Plasma S-Adenosylhomocysteine Is a Better Biomarker of Atherosclerosis Than Homocysteine in Apolipoprotein E-Deficient Mice Fed High Dietary Methionine J. Nutr., February 1, 2008; 138(2): 311 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Wegkamp, W. van Oorschot, W. M. de Vos, and E. J. Smid Characterization of the Role of para-Aminobenzoic Acid Biosynthesis in Folate Production by Lactococcus lactis Appl. Envir. Microbiol., April 15, 2007; 73(8): 2673 - 2681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cohen-Salmon, B. Regnault, N. Cayet, D. Caille, K. Demuth, J.-P. Hardelin, N. Janel, P. Meda, and C. Petit Connexin30 deficiency causes instrastrial fluid-blood barrier disruption within the cochlear stria vascularis PNAS, April 10, 2007; 104(15): 6229 - 6234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N Haan, J. W Miller, A. E Aiello, R. A Whitmer, W. J Jagust, D. M Mungas, L. H Allen, and R. Green Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: results from the Sacramento Area Latino Study on Aging Am. J. Clinical Nutrition, February 1, 2007; 85(2): 511 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Pezzini, M Grassi, E Del Zotto, D Assanelli, S Archetti, R Negrini, L Caimi, and A Padovani Interaction of homocysteine and conventional predisposing factors on risk of ischaemic stroke in young people: consistency in phenotype-disease analysis and genotype-disease analysis J. Neurol. Neurosurg. Psychiatry, October 1, 2006; 77(10): 1150 - 1156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Selhub The Many Facets of Hyperhomocysteinemia: Studies from the Framingham Cohorts J. Nutr., June 1, 2006; 136(6): 1726S - 1730S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Symons, U. B. Zaid, C. N. Athanassious, A. E. Mullick, S. R. Lentz, and J. C. Rutledge Influence of Folate on Arterial Permeability and Stiffness in the Absence or Presence of Hyperhomocysteinemia Arterioscler. Thromb. Vasc. Biol., April 1, 2006; 26(4): 814 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. J. Kullo, G. Li, L. F. Bielak, K. R. Bailey, P. F. Sheedy II, P. A. Peyser, S. T. Turner, and S. L. R. Kardia Association of Plasma Homocysteine With Coronary Artery Calcification in Different Categories of Coronary Heart Disease Risk Mayo Clin. Proc., February 1, 2006; 81(2): 177 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J Lewis, S. Ebrahim, and G. Davey Smith Meta-analysis of MTHFR 677C->T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ, November 5, 2005; 331(7524): 1053. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Qureshi, H. Chen, A. T Brown, R. Fitzgerald, X. Zhang, J. Breckenridge, R. Kazi, A. J Crocker, M. C Stuhlingexsr, K. Lin, et al. Homocysteine-induced vascular dysregulation is mediated by the NMDA receptor Vascular Medicine, August 1, 2005; 10(3): 215 - 223. [Abstract] [PDF]
|
|
|
|
|
|
C. Williams, B. A Kingwell, K. Burke, J. McPherson, and A. M Dart Folic acid supplementation for 3 wk reduces pulse pressure and large artery stiffness independent of MTHFR genotype Am. J. Clinical Nutrition, July 1, 2005; 82(1): 26 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Frederiksen, K. Juul, P. Grande, G. B. Jensen, T. V. Schroeder, A. Tybjaerg-Hansen, and B. G. Nordestgaard Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study Blood, November 15, 2004; 104(10): 3046 - 3051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. V Dedoussis, D. B Panagiotakos, C. Chrysohoou, C. Pitsavos, A. Zampelas, D. Choumerianou, and C. Stefanadis Effect of interaction between adherence to a Mediterranean diet and the methylenetetrahydrofolate reductase 677C->T mutation on homocysteine concentrations in healthy adults: the ATTICA Study Am. J. Clinical Nutrition, October 1, 2004; 80(4): 849 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lund, L. Andersson, M. Lauria, M. Lindholm, M. F. Fraga, A. Villar-Garea, E. Ballestar, M. Esteller, and S. Zaina DNA Methylation Polymorphisms Precede Any Histological Sign of Atherosclerosis in Mice Lacking Apolipoprotein E J. Biol. Chem., July 9, 2004; 279(28): 29147 - 29154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Quadri, C. Fragiacomo, R. Pezzati, E. Zanda, G. Forloni, M. Tettamanti, and U. Lucca Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia Am. J. Clinical Nutrition, July 1, 2004; 80(1): 114 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Bieswal, S. M. Hay, C. McKinnon, B. Reusens, M. Cuignet, W. D. Rees, and C. Remacle Prenatal Protein Restriction Does Not Affect the Proliferation and Differentiation of Rat Preadipocytes J. Nutr., June 1, 2004; 134(6): 1493 - 1499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. K. Al-Delaimy, K. M. Rexrode, F. B. Hu, C. M. Albert, M. J. Stampfer, W. C. Willett, and J. E. Manson Folate Intake and Risk of Stroke Among Women Stroke, June 1, 2004; 35(6): 1259 - 1263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Nurk, G. S Tell, S. E Vollset, O. Nygard, H. Refsum, R. M Nilsen, and P. M Ueland Changes in lifestyle and plasma total homocysteine: the Hordaland Homocysteine Study Am. J. Clinical Nutrition, May 1, 2004; 79(5): 812 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Troen, E. Lutgens, D. E. Smith, I. H. Rosenberg, and J. Selhub The atherogenic effect of excess methionine intake PNAS, December 9, 2003; 100(25): 15089 - 15094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sundstrom, L. Sullivan, R. B. D'Agostino, P. F. Jacques, J. Selhub, I. H. Rosenberg, P. W.F. Wilson, D. Levy, and R. S. Vasan Plasma Homocysteine, Hypertension Incidence, and Blood Pressure Tracking: The Framingham Heart Study Hypertension, December 1, 2003; 42(6): 1100 - 1105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wolters, S. Hermann, and A. Hahn B vitamin status and concentrations of homocysteine and methylmalonic acid in elderly German women Am. J. Clinical Nutrition, October 1, 2003; 78(4): 765 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Wotherspoon, D. W Laight, K. M Shaw, and M. H Cummings Review: Homocysteine, endothelial dysfunction and oxidative stress in type 1 diabetes mellitus The British Journal of Diabetes & Vascular Disease, September 1, 2003; 3(5): 334 - 340. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Infante-Rivard, G.-E. Rivard, R. Gauthier, and Y. Theoret Unexpected Relationship between Plasma Homocysteine and Intrauterine Growth Restriction Clin. Chem., September 1, 2003; 49(9): 1476 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Deussen Adenosine--the missing link to understanding homocysteine pathogenicity or more smoke on the horizon? Cardiovasc Res, August 1, 2003; 59(2): 259 - 261. [Full Text] [PDF]
|
|
|
|
|
|
W. Sybesma, M. Starrenburg, M. Kleerebezem, I. Mierau, W. M. de Vos, and J. Hugenholtz Increased Production of Folate by Metabolic Engineering of Lactococcus lactis Appl. Envir. Microbiol., June 1, 2003; 69(6): 3069 - 3076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. El-Khairy, S. E. Vollset, H. Refsum, and P. M. Ueland Plasma Total Cysteine, Mortality, and Cardiovascular Disease Hospitalizations: The Hordaland Homocysteine Study Clin. Chem., June 1, 2003; 49(6): 895 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R. Steenge, P. Verhoef, and M. B. Katan Betaine Supplementation Lowers Plasma Homocysteine in Healthy Men and Women J. Nutr., May 1, 2003; 133(5): 1291 - 1295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M Hodgson, V. Burke, L. J Beilin, K. D Croft, and I. B Puddey Can black tea influence plasma total homocysteine concentrations? Am. J. Clinical Nutrition, April 1, 2003; 77(4): 907 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Shi, J. E. Savage, S. J. Hufeisen, L. Rauser, E. Grajkowska, P. Ernsberger, J. T. Wroblewski, J. H. Nadeau, and B. L. Roth L-Homocysteine Sulfinic Acid and Other Acidic Homocysteine Derivatives Are Potent and Selective Metabotropic Glutamate Receptor Agonists J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 131 - 142. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. L. Rensma, A. J. Apperloo, P. E. de Jong, Y.-F. Chen, P.-L. Li, and A.-P. Zou Why Does Elevated Plasma Homocysteine Result in Severe Microvascular Injury, but Not Glomerular Damage? * Response Circulation, March 25, 2003; 107 (11): e77 - e77. [Full Text] [PDF]
|
|
|
|
|
|
A. de Bree, W. M. Verschuren, A.-L. Bjorke-Monsen, N. M. van der Put, S. G Heil, F. J. Trijbels, and H. J Blom Effect of the methylenetetrahydrofolate reductase 677C->T mutation on the relations among folate intake and plasma folate and homocysteine concentrations in a general population sample Am. J. Clinical Nutrition, March 1, 2003; 77(3): 687 - 693. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Davey Smith and S. Ebrahim 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int. J. Epidemiol., February 1, 2003; 32(1): 1 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Meleady, P. M Ueland, H. Blom, A. S Whitehead, H. Refsum, L. E Daly, S. E. Vollset, C. Donohue, B. Giesendorf, I. M Graham, et al. Thermolabile methylenetetrahydrofolate reductase, homocysteine, and cardiovascular disease risk: the European Concerted Action Project Am. J. Clinical Nutrition, January 1, 2003; 77(1): 63 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Yang and J D. Erickson Influence of reporting error on the relation between blood folate concentrations and reported folic acid-containing dietary supplement use among reproductive-aged women in the United States Am. J. Clinical Nutrition, January 1, 2003; 77(1): 196 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Carmel, R. Green, D. S. Rosenblatt, and D. Watkins Update on Cobalamin, Folate, and Homocysteine Hematology, January 1, 2003; 2003(1): 62 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Lim and P. A. Cassano Homocysteine and Blood Pressure in the Third National Health and Nutrition Examination Survey, 1988-1994 Am. J. Epidemiol., December 15, 2002; 156(12): 1105 - 1113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Pacific Study Group and B. Neal Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease Journal of Renin-Angiotensin-Aldosterone System, December 1, 2002; 3(4): 270 - 276. [Abstract] [PDF]
|
|
|
|
|
|
P. Verhoef, W. J Pasman, T. van Vliet, R. Urgert, and M. B Katan Contribution of caffeine to the homocysteine-raising effect of coffee: a randomized controlled trial in humans Am. J. Clinical Nutrition, December 1, 2002; 76(6): 1244 - 1248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. I Mennen, G. P. de Courcy, J.-C. Guilland, V. Ducros, S. Bertrais, J.-P. Nicolas, M. Maurel, M. Zarebska, A. Favier, C. Franchisseur, et al. Homocysteine, cardiovascular disease risk factors, and habitual diet in the French Supplementation with Antioxidant Vitamins and Minerals Study Am. J. Clinical Nutrition, December 1, 2002; 76(6): 1279 - 1289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. De Bree, W. M. M. Verschuren, D. Kromhout, L. A. J. Kluijtmans, and H. J. Blom Homocysteine Determinants and the Evidence to What Extent Homocysteine Determines the Risk of Coronary Heart Disease Pharmacol. Rev., December 1, 2002; 54(4): 599 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S Wald, M. Law, and J. K Morris Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis BMJ, November 23, 2002; 325(7374): 1202 - 1206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Schnyder, Y. Flammer, M. Roffi, R. Pin, and O. M. Hess Plasma homocysteine levels and late outcome after coronary angioplasty J. Am. Coll. Cardiol., November 20, 2002; 40(10): 1769 - 1776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Borroni, C. Agosti, A.F. Panzali, M. Di Luca, A. Padovani, J.W. Miller, R. Green, D.M. Mungas, B.R. Reed, and W.J. Jagust Homocysteine, vitamin B6, and vascular disease in patients with AD Neurology, November 12, 2002; 59(9): 1475 - 1476. [Full Text] [PDF]
|
|
|
|
 |
|
 Homocysteine Studies Collaboration Homocysteine and Risk of Ischemic Heart Disease and Stroke: A Meta-analysis JAMA, October 23, 2002; 288(16): 2015 - 2022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Klerk, P. Verhoef, R. Clarke, H. J. Blom, F. J. Kok, E. G. Schouten, and and the MTHFR Studies Collaboration Group MTHFR 677C->T Polymorphism and Risk of Coronary Heart Disease: A Meta-analysis JAMA, October 23, 2002; 288(16): 2023 - 2031. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. O'Callaghan, R. Meleady, T. Fitzgerald, I. Graham, and European COMAC group Smoking and plasma homocysteine Eur. Heart J., October 2, 2002; 23(20): 1580 - 1586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Li, F.-X. Yi, E. Rute, D. X. Zhang, G. R. Slocum, and A.-P. Zou Effects of homocysteine on intracellular nitric oxide and superoxide levels in the renal arterial endothelium Am J Physiol Heart Circ Physiol, September 1, 2002; 283(3): H1237 - H1243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Ashfield-Watt, C. H Pullin, J. M Whiting, Z. E Clark, S. J Moat, R. G Newcombe, M. L Burr, M. J Lewis, H. J Powers, and I. F. McDowell Methylenetetrahydrofolate reductase 677C->T genotype modulates homocysteine responses to a folate-rich diet or a low-dose folic acid supplement: a randomized controlled trial Am. J. Clinical Nutrition, July 1, 2002; 76(1): 180 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. B. Feldman The Scientific Evidence for a Beneficial Health Relationship Between Walnuts and Coronary Heart Disease J. Nutr., May 1, 2002; 132(5): 1062S - 1101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. V. Chirieac, T. A. Pearson, A. G. Bostom, B. Sharaf, N. Miele, G. Schnyder, and Z. G. Turi B Vitamins and Restenosis after Coronary Angioplasty N. Engl. J. Med., April 4, 2002; 346(14): 1093 - 1095. [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Gonzalez-Clemente, R. Deulofeu, J. Mitjavila, G. Galdon, E. Ortega, A. Caixas, G. Gimenez-Perez, and D. Mauricio Plasma Homocysteine Is not Increased in Microalbuminuric Patients With Type 2 Diabetes Without Clinical Cardiovascular Disease Diabetes Care, March 1, 2002; 25(3): 632 - 633. [Full Text] [PDF]
|
|
|
|
|
|
V. J. Howard, E. G. Sides, G. C. Newman, S. N. Cohen, G. Howard, M. R. Malinow, and J. F. Toole Changes in Plasma Homocyst(e)ine in the Acute Phase After Stroke Stroke, February 1, 2002; 33(2): 473 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-J. Hung, P.-C. Huang, S.-C. Lu, Y.-H. Li, H.-B. Huang, B.-F. Lin, S.-J. Chang, and H.-F. Chou Plasma Homocysteine Levels in Taiwanese Vegetarians Are Higher than Those of Omnivores J. Nutr., February 1, 2002; 132(2): 152 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. F. Jacques, R. Kalmbach, P. J. Bagley, G. T. Russo, G. Rogers, P. W. F. Wilson, I. H. Rosenberg, and J. Selhub The Relationship between Riboflavin and Plasma Total Homocysteine in the Framingham Offspring Cohort Is Influenced by Folate Status and the C677T Transition in the Methylenetetrahydrofolate Reductase Gene J. Nutr., February 1, 2002; 132(2): 283 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Li, Y.-F. Chen, and A.-P. Zou Implications of Hyperhomocysteinemia in Glomerular Sclerosis in Hypertension Hypertension, February 1, 2002; 39(2): 443 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M Kerins, M. J Koury, A. Capdevila, S. Rana, and C. Wagner Plasma S-adenosylhomocysteine is a more sensitive indicator of cardiovascular disease than plasma homocysteine Am. J. Clinical Nutrition, December 1, 2001; 74(6): 723 - 729. [Abstract] [Full Text]
|
|
|
|
|
|
S. Yap, G. H.J. Boers, B. Wilcken, D. E.L. Wilcken, D. P. Brenton, P. J. Lee, J. H. Walter, P. M. Howard, and E. R. Naughten Vascular Outcome in Patients With Homocystinuria due to Cystathionine {beta}-Synthase Deficiency Treated Chronically: A Multicenter Observational Study Arterioscler. Thromb. Vasc. Biol., December 1, 2001; 21(12): 2080 - 2085. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Cuskelly, P. W. Stacpoole, J. Williamson, T. G. Baumgartner, and J. F. Gregory III Deficiencies of folate and vitamin B6 exert distinct effects on homocysteine, serine, and methionine kinetics Am J Physiol Endocrinol Metab, December 1, 2001; 281(6): E1182 - E1190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. de Meer, F. Stam, and C. van Guldener Hyperhomocysteinemia and cardiovascular disease Am. J. Clinical Nutrition, May 1, 2001; 73(5): 992 - 993. [Full Text]
|
|
|
|
|
|
J. M Scott Homocysteine and cardiovascular risk Am. J. Clinical Nutrition, August 1, 2000; 72(2): 333 - 334. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
